CoChat
Sign Up
Cited by 36Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchIntracerebral and Subarachnoid Hemorrhage Research

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Incidence of Amyloid-Related Imaging Abnormalities in Phase III Clinical Trials of Anti-Amyloid-β Immunotherapy: An Updated Meta-Analysis

Jeong, So Yeong, Suh, Chong Hyun, Lim, Jae-Sung, Shim, Woo Hyun, Heo, Hwon, Choi, Yangsean, Kim, Ho Sung, Kim, Sang Joon, Lee, Jae-Hong·2025·Neurology
DOI 10.1212/wnl.0000000000213483
Open this paper in CoChat — free account

Abstract

Background and objectives Amyloid-related imaging abnormalities (ARIA) are key safety considerations in anti-amyloid-β (Aβ) immunotherapy. ARIA can be categorized into 2 types: ARIA characterized by edema and effusion (ARIA-E) or microhemorrhages and superficial siderosis (ARIA-H). In this study, we assessed the incidence of ARIA in phase 3 randomized controlled trials (RCTs) of anti-Aβ immunotherapy and compared the incidence among different agents and APOE ε4 carrier status. Methods PubMed and Embase databases were searched for phase 3 RCTs of anti-Aβ immunotherapy published on or before May 23, 2024. The inclusion criteria were phase 3 trials of anti-Aβ immunotherapy for mild cognitive impairment due to Alzheimer disease (AD) or mild AD dementia, with sufficient data on ARIA-E/H. The pooled incidences of ARIA and subgroup analyses according to various agents and APOE ε4 carrier status were calculated. A sensitivity analysis excluding outliers was performed. The pooled odds ratio (OR) of ARIA-E according to the APOE ε4 carrier status was also calculated. Results Nine phase 3 RCT cohorts from 8 eligible studies were identified, analyzing data from 6,315 patients. The pooled incidence of ARIA-E was 9.5% (95% CI 2.8%-27.3%), and the adjusted pooled incidence of ARIA-E was 25.5% (95% CI 20.4%-31.8%) in the sensitivity analysis. The pooled incidence of symptomatic ARIA-E was 6.7% (95% CI 3.5%-12.5%) and that of severe ARIA-E was 3.5% (95% CI 13.8%-8.4%). The pooled incidence of…

Overview

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000213483

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 9 references

Research works printed but not linked: 30

  1. 10.1001/jamaneurol.2013.5847 · DOI
  2. 10.1212/wnl.51.1_suppl_1.s2 · DOI
  3. 10.1001/jamaneurol.2019.1424 · DOI · Paper page
  4. 10.1097/00002826-200405000-00011 · DOI
  5. 10.3174/ajnr.A8469 · DOI
  6. 10.14283/jpad.2021.41 · DOI · Paper page
  7. 10.1212/WNL.0000000000201019 · DOI
  8. 10.3348/kjr.2021.0963 · DOI
  9. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions: Version 5.1.0. The Cochrane Collaboration. Updated March 2011. Accessed October 2, 2017. handbook-5-1.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm.
  10. 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  11. 10.1136/bmj.315.7109.629 · DOI · Paper page
  12. 10.14283/jpad.2022.30 · DOI · Paper page
  13. 10.1186/s13195-024-01441-8 · DOI
  14. 10.1001/jamaneurol.2022.2909 · DOI
  15. 10.1001/jamaneurol.2021.4161 · DOI · Paper page
  16. 10.1001/jama.2023.13239 · DOI · Paper page
  17. 10.1056/NEJMoa2212948 · DOI · Paper page
  18. 10.3174/ajnr.A7586 · DOI
  19. 10.1212/WNL.0000000000008590 · DOI
  20. 10.1212/WNL.0000000000006956 · DOI
  21. 10.1186/s40478-023-01714-7 · DOI
  22. 10.1212/WNL.0000000000209674 · DOI
  23. 10.1212/WNL.0000000000209582 · DOI
  24. 10.1038/s41467-023-43933-5 · DOI
  25. 10.3233/JAD-221305 · DOI
  26. 10.1212/WNL.0000000000012778 · DOI
  27. 10.1002/ana.24135 · DOI · Paper page
  28. 10.1016/j.jalz.2018.04.010 · DOI · Paper page
  29. 10.1001/jama.1997.03550160069041 · DOI · Paper page
  30. 10.1001/jama.1994.03510410028015 · DOI · Paper page

Cited by

Sorted by citations

See all 36

Metadata

Authors
Jeong, S. Y., Suh, C. H., Lim, J.-S., Shim, W. H., Heo, H., Choi, Y., Kim, H. S., Kim, S. J., & Lee, J.-H.
Affiliations
  • Seoul National University Bundang Hospital (KR)
  • Asan Medical Center (KR)
ORCID
Venue
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2025-04-22
Volume
104
Issue
8
Pages
e213483-e213483
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
DOI
10.1212/wnl.0000000000213483
OpenAlex
W4408667303
Cited by
36
References
9
Citations by year
2026: 31 · 2025: 5
FWCI
22.98
Type
journal article
Language
en
Open access
closed
Locations
  • Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
Keywords
amyloid-related imaging abnormalities, ARIA-E, ARIA-H, amyloid-beta, APOE ε4, drug safety, Alzheimer's disease
MeSH terms
Alzheimer Disease, Humans, Immunotherapy, Incidence, Randomized Controlled Trials as Topic, Amyloid beta-Peptides, Clinical Trials, Phase III as Topic, Apolipoprotein E4, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review